49598-6
Natalizumab Ab [Presence] in Serum by Immunoassay
Active
Part Descriptions
LP64671-8 Natalizumab
Natalizumab is a humanized monoclonal antibody against the cellular adhesion molecule α4-integrin. Natalizumab is used in the treatment of multiple sclerosis and Crohn's disease. The drug is believed to work by reducing the ability of inflammatory immune cells to attach to and pass through the cell layers lining the intestines and blood-brain barrier. Natalizumab has proven effective in treating the symptoms of both diseases, preventing relapse, vision loss, cognitive decline and significantly improving quality of life in people with multiple sclerosis, as well as increasing rates of remission and preventing relapse in Crohn's disease.
Copyright Text is available under the Creative Commons Attribution/Share-Alike License. See http://creativecommons.org/licenses/by-sa/3.0/ for details.
Source: Wikipedia, Wikipedia
LP64672-6 Natalizumab Ab
Drug therapy for MS - loses effectiveness when patients develop antibodies to the drug. Detecting the antibodies early allows healthcare providers the opportunity to prescribe alternative therapy and avoid the cost associated with failed therapy.
Source: Regenstrief Institute
Fully-Specified Name
- Component
- Natalizumab Ab
- Property
- PrThr
- Time
- Pt
- System
- Ser
- Scale
- Ord
- Method
- IA
Additional Names
- Long Common Name
- Natalizumab Ab [Presence] in Serum by Immunoassay
- Short Name
- Natalizumab Ab Ser Ql IA
- Display Name
- Natalizumab Ab IA Ql (S)
- Consumer Name Alpha Get Info
- Natalizumab antibody, Blood
Example Answer List: LL360-9
Source: Regenstrief InstituteAnswer | Code | Score | Answer ID |
---|---|---|---|
PositiveCopyright http://snomed.info/sct ID:10828004 Positive (qualifier value) | LA6576-8 | ||
NegativeCopyright http://snomed.info/sct ID:260385009 Negative (qualifier value) | LA6577-6 |
Basic Attributes
- Class
- SERO
- Type
- Laboratory
- First Released
- Version 2.22
- Last Updated
- Version 2.73
- Change Reason
- The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.; The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016.
- Order vs. Observation
- Both
- Common Test Rank Get Info
- 8987
Member of these Groups Get Info
LOINC Group | Group Name |
---|---|
LG19693-7 | Natalizumab Ab| |
Language Variants Get Info
Tag | Language | Translation |
---|---|---|
es-ES | Spanish (Spain) | Natilizumab Anticuerpos: |
es-MX | Spanish (Mexico) | Natalizumab Ab: |
et-EE | Estonian (Estonia) | Natalisumaab antikehad: Synonyms: Järgarvuline Juhuslik Seerum |
fr-CA | French (Canada) | Natalizumab, Ac: |
fr-FR | French (France) | Natalizumab anticorps: |
fr-BE | French (Belgium) | Natalizumab Ac: Synonyms: Anticorps |
it-IT | Italian (Italy) | Natalizumab Ab: Synonyms: anticorpo Immunoassay Presenza o Soglia Punto nel tempo (episodio) Siero Sierologia (anticorpi e la maggior parte degli ant |
nl-NL | Dutch (Netherlands) | natalizumab As: Synonyms: antistof; |
pt-BR | Portuguese (Brazil) | NatalizumAc Ac: Synonyms: TysAcri; |
ru-RU | Russian (Russian Federation) | Натализумаб Ат: Synonyms: Антитело Порядковый Сыворотка Точка во времени; |
tr-TR | Turkish (Turkey) | Natalizumab Ab: Synonyms: Ak İmmünölçüm, immünoassay Mevcut |
uk-UA | Ukrainian (Ukraine) | Наталізумаб Антитіла: Synonyms: ABS; |
zh-CN | Chinese (China) | 那他珠单抗 抗体: Synonyms: Ab; |
LOINC Terminology Service (API) using HL7® FHIR® Get Info
Requests to this service require a free LOINC username and password. Below is a sample of the possible capabilities. See the LOINC Terminology Service documentation for more information.
- CodeSystem lookup
- https:
//fhir.loinc.org/CodeSystem/$lookup?system=http: //loinc.org&code=49598-6
Third Party Copyright
This material includes SNOMED Clinical Terms® (SNOMED CT®) which is used by permission of the International Health Terminology Standards Development Organisation (IHTSDO) under license. All rights reserved. SNOMED CT® was originally created by The College of American Pathologists. "SNOMED" and "SNOMED CT" are registered trademarks of the IHTSDO.
This material includes content from the US Edition to SNOMED CT, which is developed and maintained by the U.S. National Library of Medicine and is available to authorized UMLS Metathesaurus Licensees from the UTS Downloads site at https://uts.nlm.nih.gov.
Use of SNOMED CT content is subject to the terms and conditions set forth in the SNOMED CT Affiliate License Agreement. It is the responsibility of those implementing this product to ensure they are appropriately licensed and for more information on the license, including how to register as an Affiliate Licensee, please refer to http://www.snomed.org/snomed-ct/get-snomed-ct or info@snomed.org<mailto:info@snomed.org>. This may incur a fee in SNOMED International non-Member countries.
LOINC Copyright
Copyright © 2024 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright © Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. See https://